Skip To Main Content
Michelle Carr on Muck Rack

Michelle Carr

As seen in: Dallas Business Journal, The Dodo, Lexology, Isanti-Chisago County Star, RVwest, Connect on Tech
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michelle

Contact Michelle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion

|
By Michael DeFranco, Michelle Carr
| Connect on Tech
Baker McKenzie is representing Servier, an independent international pharmaceutical group governed by a foundation, on its definitive agreement to acquire Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with life threatening diseases, for approximately USD 2.5 billion.
Open in Who Shared Issue with article?

International: Manufacturing Site Divestitures

|
By Michelle Carr, Xin Tao, Daniel Garcia, Lois Sheng Liu
| bakermckenzie.com
In brief Pharmaceutical companies are increasingly outsourcing complex manufacturing activities to contract development and manufacturing organizations (CDMOs). This enables pharmaceutical companies to streamline their operations and redeploy capital toward research and development activities. At the same time, the CDMO industry is booming, with many analysts predicting continued rapid growth. CDMOs need more capacity, and they need it quickly.
Open in Who Shared Issue with article?

Manufacturing Site Divestitures: Best Practices for Successful Execution

|
By Michelle Carr, Daniel Garcia, Lois Sheng Liu, Xin Tao
| Lexology Verified
Pharmaceutical companies are increasingly outsourcing complex manufacturing activities to contract development and manufacturing organizations, or CDMOs. This enables pharmaceutical companies to streamline their operations and redeploy capital toward research and development activities. At the same time, the CDMO industry is booming, with many analysts predicting continued rapid growth. CDMOs need more capacity, and they need it quickly.
Open in Who Shared Issue with article?
See all 11 articles